Literature DB >> 19808337

Circulating plasma surfactant protein type B as biological marker of alveolar-capillary barrier damage in chronic heart failure.

Damiano Magrì1, Maura Brioschi, Cristina Banfi, Jean Paul Schmid, Pietro Palermo, Mauro Contini, Anna Apostolo, Maurizio Bussotti, Elena Tremoli, Susanna Sciomer, Gaia Cattadori, Cesare Fiorentini, Piergiuseppe Agostoni.   

Abstract

BACKGROUND: Surfactant protein type B (SPB) is needed for alveolar gas exchange. SPB is increased in the plasma of patients with heart failure (HF), with a concentration that is higher when HF severity is highest. The aim of this study was to evaluate the relationship between plasma SPB and both alveolar-capillary diffusion at rest and ventilation versus carbon dioxide production during exercise. METHODS AND
RESULTS: Eighty patients with chronic HF and 20 healthy controls were evaluated consecutively, but the required quality for procedures was only reached by 71 patients with HF and 19 healthy controls. Each subject underwent pulmonary function measurements, including lung diffusion for carbon monoxide and membrane diffusion capacity, and maximal cardiopulmonary exercise test. Plasma SPB was measured by immunoblotting. In patients with HF, SPB values were higher (4.5 [11.1] versus 1.6 [2.9], P=0.0006, median and 25th to 75th interquartile), whereas lung diffusion for carbon monoxide (19.7+/-4.5 versus 24.6+/-6.8 mL/mm Hg per min, P<0.0001, mean+/-SD) and membrane diffusion capacity (28.9+/-7.4 versus 38.7+/-14.8, P<0.0001) were lower. Peak oxygen consumption and ventilation/carbon dioxide production slope were 16.2+/-4.3 versus 26.8+/-6.2 mL/kg per min (P<0.0001) and 29.7+/-5.9 and 24.5+/-3.2 (P<0.0001) in HF and controls, respectively. In the HF population, univariate analysis showed a significant relationship between plasma SPB and lung diffusion for carbon monoxide, membrane diffusion capacity, peak oxygen consumption, and ventilation/carbon dioxide production slope (P<0.0001 for all). On multivariable logistic regression analysis, membrane diffusion capacity (beta, -0.54; SE, 0.018; P<0.0001), peak oxygen consumption (beta, -0.53; SE, 0.036; P=0.004), and ventilation/carbon dioxide production slope (beta, 0.25; SE, 0.026; P=0.034) were independently associated with SPB.
CONCLUSIONS: Circulating plasma SPB levels are related to alveolar gas diffusion, overall exercise performance, and efficiency of ventilation showing a link between alveolar-capillary barrier damage, gas exchange abnormalities, and exercise performance in HF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808337     DOI: 10.1161/CIRCHEARTFAILURE.108.819607

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  9 in total

Review 1.  Lung morphology and surfactant function in cardiogenic pulmonary edema: a narrative review.

Authors:  Kenneth Nugent; Logan Dobbe; Rubayat Rahman; Mohamed Elmassry; Pablo Paz
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

Review 2.  Biomarkers of lung injury in cardiothoracic surgery.

Authors:  Gerwin Erik Engels; Willem van Oeveren
Journal:  Dis Markers       Date:  2015-03-17       Impact factor: 3.434

3.  Fetal and neonatal samples of a precursor surfactant protein B inversely related to gestational age.

Authors:  Christoph Czernik; Gerd Schmalisch; Christoph Bührer; Hans Proquitté
Journal:  BMC Pediatr       Date:  2013-10-10       Impact factor: 2.125

4.  Surfactant-derived proteins as markers of alveolar membrane damage in heart failure.

Authors:  Paola Gargiulo; Cristina Banfi; Stefania Ghilardi; Damiano Magrì; Marta Giovannardi; Alice Bonomi; Elisabetta Salvioni; Elisa Battaia; Pasquale Perrone Filardi; Elena Tremoli; Piergiuseppe Agostoni
Journal:  PLoS One       Date:  2014-12-16       Impact factor: 3.240

5.  High postoperative serum levels of surfactant type B as novel prognostic markers for congenital heart surgery.

Authors:  Onur IsiK; Olcay Murat Disli; Tolga Bas; Hakan AydiN; Murat Koç; Ali Kutsal
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Apr-Jun

Review 6.  Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan.

Authors:  Piergiuseppe Agostoni; Dimitrios T Farmakis; Jose M García-Pinilla; Veli-Pekka Harjola; Kristjan Karason; Dirk von Lewinski; John Parissis; Piero Pollesello; Gerhard Pölzl; Alejandro Recio-Mayoral; Alexander Reinecke; Patrik Yerly; Endre Zima
Journal:  Card Fail Rev       Date:  2019-11-04

7.  Multiplexed MRM-Based Proteomics Identified Multiple Biomarkers of Disease Severity in Human Heart Failure.

Authors:  Maura Brioschi; Erica Gianazza; Piergiuseppe Agostoni; Beatrice Zoanni; Alice Mallia; Cristina Banfi
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

8.  Lungs in heart failure.

Authors:  Anna Apostolo; Giuliano Giusti; Paola Gargiulo; Maurizio Bussotti; Piergiuseppe Agostoni
Journal:  Pulm Med       Date:  2012-12-24

9.  Soluble receptor for advanced glycation end products as an indicator of pulmonary vascular injury after cardiac surgery.

Authors:  Pieter R Tuinman; Alexander D Cornet; Maria T Kuipers; Alexander P Vlaar; Marcus J Schultz; Albertus Beishuizen; A B Johan Groeneveld; Nicole P Juffermans
Journal:  BMC Pulm Med       Date:  2013-12-16       Impact factor: 3.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.